219 related articles for article (PubMed ID: 35563509)
1. Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis.
Chen LY; Huang RL; Su PH; Chu LH; Weng YC; Wang HC; Lai HC; Wen KC
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563509
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
5. Epigenetic targeting of ovarian cancer stem cells.
Wang Y; Cardenas H; Fang F; Condello S; Taverna P; Segar M; Liu Y; Nephew KP; Matei D
Cancer Res; 2014 Sep; 74(17):4922-36. PubMed ID: 25035395
[TBL] [Abstract][Full Text] [Related]
6. Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles.
Yousefi M; Dehghani S; Nosrati R; Ghanei M; Salmaninejad A; Rajaie S; Hasanzadeh M; Pasdar A
Cell Oncol (Dordr); 2020 Aug; 43(4):515-538. PubMed ID: 32418122
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer.
Li Y; Wang W; Wang D; Zhang L; Wang X; He J; Cao L; Li K; Xie H
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553542
[TBL] [Abstract][Full Text] [Related]
9. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.
Wang Y; Zong X; Mitra S; Mitra AK; Matei D; Nephew KP
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518684
[TBL] [Abstract][Full Text] [Related]
10. A methylation-driven genes prognostic signature and the immune microenvironment in epithelial ovarian cancer.
Tan M; Wang S; Li F; Xu H; Gao J; Zhu L
Carcinogenesis; 2022 Aug; 43(7):635-646. PubMed ID: 35639961
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
Qiu JJ; Lin XJ; Tang XY; Zheng TT; Zhang XY; Hua KQ
Int J Cancer; 2020 May; 146(9):2588-2598. PubMed ID: 31577838
[TBL] [Abstract][Full Text] [Related]
12. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
13. High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer.
Zhang L; Chen H; Ding B; Jiang W
J Ovarian Res; 2022 Feb; 15(1):19. PubMed ID: 35105347
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
15. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.
Liu M; Mor G; Cheng H; Xiang X; Hui P; Rutherford T; Yin G; Rimm DL; Holmberg J; Alvero A; Silasi DA
Reprod Sci; 2013 May; 20(5):605-15. PubMed ID: 23171677
[TBL] [Abstract][Full Text] [Related]
16. Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
Lupia M; Melocchi V; Bizzaro F; Lo Riso P; Dama E; Baronio M; Ranghiero A; Barberis M; Bernard L; Bertalot G; Giavazzi R; Testa G; Bianchi F; Cavallaro U
Int J Cancer; 2022 Jul; 151(2):240-254. PubMed ID: 35218560
[TBL] [Abstract][Full Text] [Related]
17. DEAD-Box Helicase 4 (Ddx4)
D'Oronzo S; Silvestris E; Lovero D; Cafforio P; Duda L; Cormio G; Paradiso A; Palmirotta R; Silvestris F
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847044
[TBL] [Abstract][Full Text] [Related]
18. Involvement of Cancer Stem Cells in Chemoresistant Relapse of Epithelial Ovarian Cancer Identified by Transcriptome Analysis.
Sun Y; Yao L; Wang C; Xiong B; Guo J; Wang L; Zhu J; Cheng Z; Liu S
J Oncol; 2022; 2022():6406122. PubMed ID: 35401749
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer.
Chen Y; Zhang L; Lv R; Zhang WQ
Asian Pac J Cancer Prev; 2013; 14(10):5883-90. PubMed ID: 24289594
[TBL] [Abstract][Full Text] [Related]
20. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
